Summary
Patient preferences when using medicine is already part of the approval process for new medicines in FDA and EMA.
At this hot topic seminar, you gain an understanding of how patient involvement and patient preferences can be used to demonstrate the value of pharmaceutical products. You will hear, how a hospital doctor systematically has increased patient adherence through more patient involvement . You will also hear a representative from a pharmaceutical company present how they successfully made use of patient preferences to generate positive patient outcomes for a new innovative medicinal product. Last but least, the chairman of the Danish Medicines Council will present how they regard the use of such data in relation to strengthening a HTA application.
Keywords
- Patient preferences
- Patient Advocacy
- Patient involvement
- Medical Affairs
- HTA processes
Save information for later

Course leader & lecturers
- Elisabeth Gammelgaard LudvigCourse leaderOwner
Sundhedsagenda - Agathe Le LayLecturerVice President, Global Head of Value Evidence
Lundbeck A/S - Jacoline BouvyLecturerTechnical Director
National Institute for Health and Care Excellence (NICE) - Karina Dahl SteffensenLecturerProfessor, Cheflæge, Center for Fælles Beslutningstagning
Sygehus Lillebælt, Syddansk Universitetshospital - Jørgen Schøler KristensenLecturerKst Koncerndirektør
Medicinrådet
Is this course for you?
Join this seminar if you work in a consultancy or pharmaceutical company within medical affairs, market access, public affairs, sales & marketing, or patient advocacy.
What you will learn
- Understand what patient preferences are, and how they can be generated qualitatively and quantitatively.
- Learn how The Danish Medicines Council views patient preference data, and how and if it expects to include patient preferences in its future considerations.
- Learn how a pharma HQ works with patient preference data in HTA processes.
- Understand how Danish HCPs work with patient involvement and patient preferences in joint decision making when choosing treatment type, and how pharma companies can support this work.
What your company will get
- An employee who understands patient preferences and how these can be developed.
- An employee who understands how patient preferences can be utilised in cross-functional work within a pharma company in drug development, during market access and during launch.
Course information
Literature
Recommended readings:
Metodehaandbog-for-terapiomraader_adlegacy.pdf(medicinraadet.dk) (sections 3 and 4.1.2)
Prerequisites
Industry knowledge is an advantage.
Examination
There is no examination for this course.
Course leader
Sundhedsagenda
Lecturers
Lundbeck A/S
National Institute for Health and Care Excellence (NICE)
Sygehus Lillebælt, Syddansk Universitetshospital
Medicinrådet
You may also be interested in these courses
Want to know more or need help?
Contact Client Manager Christina Spangsberg at +45 39 15 09 22